MCMs expression in lung cancer: implication of prognostic significance.

Minichromosome Maintenance (MCM) proteins play essential roles in various cancers. We previously reported that MCM7 could be a prognostic biomarker in non-small cell lung cancer (NSCLC). The purpose of current study is to explore roles of other MCM proteins in NSCLC and their correlation with clinico-pathologic parameters of NSCLC patients. We evaluated the expression of MCM2, MCM5 and MCM6 immunohistochemically in 571 primary NSCLC samples. High expression of MCM2, MCM5 and MCM6 was detected in 42.2%, 38.3% and 52.9% of tumor tissues, respectively. The expression of MCM2, MCM5 and MCM6 was significantly associated with gender ( P = 0.00004, 0.00004, 0.008), tumor type ( P < 0.00001, < 0.00001, 0.00001) and smoking history ( P = 0.009, 0.00043, 0.002). MCM2 and MCM5 were detected more in central-type lung cancer ( P< 0.006, 0.016). Higher labeling index (LI) of MCM2 was observed more frequently in aged patients ( P = 0.023) and in those at later stage ( P = 0.001). Higher MCM5 LIs was detected more in patients with distant metastasis ( P = 0.008). Kaplan-Meier curves indicated that early-stage (stage I/II) patients with higher MCM2 LIs had a poorer OS compared to those with lower LIs ( P = 0.021). And lung squamous cell carcinoma (SCC) patients presenting high MCM5 expression had shorter OS ( P = 0.015). Multivariate Cox regression analysis showed that MCM5 was an independent prognostic indicator ( P = 0.035, HR = 1.586, 95%CI: 1.032-2.437). We reported for the first time that higher MCM5 LIs could be an independent adverse prognostic biomarker for SCC patients.